Neovascular Age-Related Macular Degeneration and GLP-1 RAs—Reply
In Reply We read the letters with great interest commenting on our recent article. We agree that surveillance bias is a concern in observational studies using administrative data. To mitigate this, we implemented several methodological approaches. First, we used duration of diabetes as a covariate in propensity score matching, which serves as a proxy for […]
Rise of Direct-to-Patient GLP-1 Sales Shakes Up Care Models, HCPs Split on Pharma’s Expanding Role
NEW YORK–(BUSINESS WIRE)–The 43rd Barometer from Sermo, a fast, frictionless HCP social engagement platform and leader in healthcare insights, shows that pharma-led direct-to-patient (DTP) GLP-1 prescribing programs are transforming treatment access pathways. Yet findings from 953 surveyed GLP-1 prescribers reveal sharp divisions over how involved pharma should be in clinical evaluation and prescribing. DTP Models […]
More GLP-1s aim to enter US market
Novo Nordisk is seeking FDA approval for an experimental obesity shot, CagriSema (cagrilintide and semaglutide), according to a Dec. 18 news release from the Denmark-based drugmaker. CagriSema is a weekly injection of semaglutide, a GLP-1, and cagrilintide, a long-acting amylin analogue. If approved, the drug would be the first injectable GLP-1 and amylin analogue combination […]
Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?
Novo Nordisk NVO is a leading player in the obesity market, driven by its blockbuster GLP-1 therapy Wegovy (semaglutide). However, despite being a core growth driver, Wegovy’s sales momentum has slowed in recent quarters. The deceleration is primarily attributed to intensifying competition in the GLP-1 space, most notably from its arch-rival Eli Lilly LLY, as well […]
STAT+: Pharmalittle: We’re reading about Lilly’s obesity pill, pharma deals with Trump, and much more
Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are enveloping the Pharmalot campus, where the official mascots are foraging for noshes and keeping strangers at bay. As for us, we are engaged in the usual rituals, starting with firing up the coffee kettle — our […]
Mazdutide versus placebo in Chinese adults with type 2 diabetes – Nature
Mazdutide versus placebo in Chinese adults with type 2 diabetes Nature Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature Yahoo Finance Phase 3 Trial Shows Mazdutide Improves Blood Sugar Control in Type 2 Diabetes Patients geneonline.com 来曲肽对比度拉糖肽治疗中国2型糖尿病 Bioengineer.org 马兹杜替德对比安慰剂治疗2型糖尿病 Bioengineer.org
How weight-loss jabs are changing the way we eat
Babybel, the “small, ready-to-eat industrial cheese wrapped in its signature red wax”, is an unexpected beneficiary of anti-obesity drugs, said Le Monde. Its French-owned producer Bel is investing €60 million to ramp up production of the cheese in response to a 6% growth in global sales, and a 12% increase in the US. Healthy snacks […]
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial – Eli Lilly
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Eli Lilly Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound CNBC People Are Already Taking This Unapproved New Weight-Loss Drug WIRED Lilly’s obesity pill largely maintains weight lost on injectable […]
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly – CNBC
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly CNBC Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management Yahoo Finance A new generation of weight-loss drugs is getting closer to patients. Here’s how they differ from Wegovy and Zepbound. MarketWatch […]
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound – CNBC
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound CNBC Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Eli Lilly People Are Already Taking This Unapproved New Weight-Loss Drug WIRED Major Weight Loss and Knee-Pain Relief Seen With New […]